UGREEN's 2-in-1 Magnetic Foldable Charging Station Has Never Been This Cheap, Early Prime Day Makes It Happen
See at Amazon
This 2-in-1 charger is built from the ground up for Apple users to be able to wirelessly chargie their iPhone, AirPods, and Apple Watch. The charger features two panels for wireless charging of differing sizes to match each of those three. As a wireless charger, it'll support generations of iPhone from the 12 and up, the most recent generation of AirPods cases, and every Apple Watch.
One of the most remarkable aspects of this wireless charging station is just how efficient it is in the space it takes up. It's just the two connected panels that when not in use, can be folded into a pocket-sized form to be taken with you wherever you go. That means your on your next business trip or weekend getaway, you only need take this charging station with you as opposed to three individual cables and adapters.
The wireless charging panels can recharge your phone at 15W. While it's charging, the stand can be adjusted so you can keep using your phone. The angle can be modified up to 60° to keep it ideal for viewing your phone screen while keeping the charging stand comfortably on your desk. You can even rotate your phone a full 360° so you can use it either vertically or horizontally. That's great if you're someone like me who like to watch YouTube videos while eating lunch. It's great for desktops and bedsides alike.
For a limited time, you can score the UGREEN MagFlow Qi2 magnetic foldable charger for a nice 30% discount. That saves you a solid $15, bringing the price down from $50 to a much more palatable $35. This is the lowest price we've seen the UGREEN 2-in-1 charger going for ever.
See at Amazon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
Washington Post
11 minutes ago
- Washington Post
China summons Nvidia over backdoor security concerns with AI chips
China's cyberspace regulator said Thursday that it had summoned representatives of U.S. tech giant Nvidia to explain alleged security vulnerability risks involving its highly sought-after H20 artificial intelligence chips. This comes barely two weeks after the Trump administration suddenly reversed its ban and allowed the Silicon Valley company to resume exports of the chips to China, part of broader de-escalation ahead of trade talks.
New York Times
11 minutes ago
- New York Times
China Summons Nvidia Over ‘Backdoor Security' Risks of A.I. Chips
China's internet regulator, the Cyberspace Administration of China, announced on Thursday that it had summoned Nvidia to explain security risks associated with one of its artificial intelligence chips developed for the Chinese market. The regulator said it had requested that Nvidia explain 'backdoor security risks associated with its H20 computing chips sold to China and submit relevant supporting documentation,' citing information it said had been revealed by 'U.S. artificial intelligence experts' that the company's chips could be shut down remotely or used to track a user's location. The H20 has been at the center of the increasingly heated contest between the United States and China for primacy over artificial intelligence. Earlier this month, Nvidia's chief executive, Jensen Huang, persuaded the Trump administration to lift an earlier ban on sales of the chip to China, in a remarkable reversal of a yearslong effort by officials in Washington to slow Beijing's technological and military progress. Mr. Huang met in recent weeks with senior officials in both Washington and Beijing, where he repeated his argument that American technology companies must do business in China to stay competitive. Former top officials in the administration of President Joseph R. Biden Jr. have warned that allowing Nvidia to sell the chips in China could set Chinese companies up to gain an irreversible dominance over artificial intelligence. The H20 is not Nvidia's most powerful chip, but it is coveted by Chinese companies for use in artificial intelligence systems. The reversal comes at a crucial time when Chinese A.I. companies are working to improve their technology and catch up to American rivals. China accounted for $17 billion of Nvidia's revenue during its last fiscal year, according to the advisory firm Bernstein Research, and Mr. Huang has previously said that the company expected to sell billions of dollars of chips in China this year. In Beijing earlier this month, Mr. Huang declined to estimate exactly how many H20 chips would now be sold in China. Nvidia did not immediately respond to a request for comment. Siyi Zhao contributed research from Beijing.
